CyanVac subsidiary Blue Lake Biotechnology said that dosing has begun in a Phase 1 clinical trial of the company’s BLB-201 intranasal vaccine against respiratory syncytial virus. The open label trial is expected to enroll 15 healthy adults aged 18 to 59 and 15 adults aged 60 to 75 who will each receive a single intranasal dose of BLB-201.
The company had announced plans for the trial in March 2022 after the FDA cleared an IND for BLB-201. In May 2022, the FDA granted Fast Track designation to the vaccine, which is based on an attenuated strain of canine parainfluenza virus (PIV5).
CyanVac and Blue Lake are developing several other intranasal vaccines on the same platform as BLB-201 and initiated a Phase 1 trial of their CVXGA1 intranasal vaccine for COVID-19 in September 2021. Other candidates in early development include vaccines for norovirus and Lyme Disease.
Blue Lake CEO Biao He commented, “The enrollment of the first participant in this RSV vaccine study is an important milestone for Blue Lake. We now have two clinical stage programs – a COVID-19 vaccine and an RSV vaccine using our intranasal PIV5-vectored vaccine platform, which we expect will confirm the broad utility of our platform.”
Read the Blue Lake Biotechnology press release.
